The price of Janux Therapeutics Inc (NASDAQ: JANX) closed at $50.00 in the last session, up 12.06% from day before closing price of $44.62. In other words, the price has increased by $+5.38 from its previous closing price. On the day, 2671880 shares were traded.
Ratios:
We take a closer look at JANX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 26.80 and its Current Ratio is at 26.80. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on March 21, 2024, initiated with a Buy rating and assigned the stock a target price of $62.
On March 20, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $100.
On April 06, 2023, Wedbush started tracking the stock assigning a Outperform rating and target price of $24.Wedbush initiated its Outperform rating on April 06, 2023, with a $24 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 13 ’23 when Avalon Ventures XI, L.P. bought 849,854 shares for $5.87 per share. The transaction valued at 4,988,643 led to the insider holds 849,854 shares of the business.
Reardon Tighe bought 849,854 shares of JANX for $4,988,643 on Nov 13 ’23. The Acting Chief Financial Officer now owns 849,854 shares after completing the transaction at $5.87 per share. On Nov 13 ’23, another insider, Lichter Jay, who serves as the Director of the company, bought 849,854 shares for $5.87 each. As a result, the insider paid 4,988,643 and bolstered with 849,854 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JANX now has a Market Capitalization of 2.30B and an Enterprise Value of 1.98B. For the stock, the TTM Price-to-Sale (P/S) ratio is 319.68 while its Price-to-Book (P/B) ratio in mrq is 6.72. Its current Enterprise Value per Revenue stands at 245.20 whereas that against EBITDA is -27.91.
Stock Price History:
Over the past 52 weeks, JANX has reached a high of $58.69, while it has fallen to a 52-week low of $5.65. The 50-Day Moving Average of the stock is 29.65, while the 200-Day Moving Average is calculated to be 15.00.
Shares Statistics:
According to the various share statistics, JANX traded on average about 793.97K shares per day over the past 3-months and 912.1k shares per day over the past 10 days. A total of 46.25M shares are outstanding, with a floating share count of 34.43M. Insiders hold about 33.35% of the company’s shares, while institutions hold 57.78% stake in the company. Shares short for JANX as of Mar 15, 2024 were 3.11M with a Short Ratio of 4.73, compared to 2.44M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.02% and a Short% of Float of 12.86%.
Earnings Estimates
The company has 7 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.34 for the current quarter, with a high estimate of -$0.29 and a low estimate of -$0.39, while EPS last year was -$0.42. The consensus estimate for the next quarter is -$0.32, with high estimates of -$0.2 and low estimates of -$0.4.
Analysts are recommending an EPS of between -$0.93 and -$1.68 for the fiscal current year, implying an average EPS of -$1.36. EPS for the following year is -$1.7, with 7 analysts recommending between -$0.99 and -$2.3.
